In a nutshell The study evaluated outcomes of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) who were continuing drugs targeting androgen receptors (AR). The authors found that BAT was clinically effective in such patients. Some background BAT refers to sequential injections with testosterone in men...
Read MoreProstate cancer Posts on Medivizor
Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer
In a nutshell The study compared the long-term effects of moderate hypofractionated intensity-modulated radiation therapy (H-IMRT) and conventionally fractionated IMRT (C-IMRT) on outcomes in patients with localized prostate cancer (PC). The authors found that H-IMRT was similarly effective compared to C-IMRT after 10 years of therapy in such...
Read MoreDoes olaparib increase survival in patients with metastatic castration-resistant prostate cancer?
In a nutshell This study assessed whether olaparib (Lynparza) affected progression-free survival (PFS; survival without cancer worsening) in patients with metastatic castration-resistant prostate cancer (mCRPC) and certain genetic mutations (abnormalities). The study found that olaparib improved PFS in these patients. Some...
Read MoreEvaluating the risk of secondary cancers after internal radiation therapy in patients with prostate cancer
In a nutshell This study looked at the long-term risk of secondary cancers following brachytherapy (BT; internal radiation therapy) for prostate cancer. It found that treating prostate cancer with BT had a low risk of secondary cancers. Some background Prostate cancer is a slow-growing cancer of the prostate gland. Men with prostate cancer that has...
Read MoreCan oral relugolix be used as androgen-deprivation therapy in advanced prostate cancer?
In a nutshell The study looked at whether oral relugolix (Orgovyx, Relumina) could be used to suppress testosterone in men with advanced prostate cancer compared to leuprolide (Lupron). This study showed that relugolix was associated with more rapid and effective suppression of testosterone levels when compared...
Read MoreDoes enzalutmide improve survival in nonmetastatic, castration-resistant prostate cancer?
In a nutshell The study assessed whether enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) increased overall survival (OS) of patients with nonmetastatic, castration-resistant prostate cancer (CRPC). The study found improved survival in patients with CRPC treated with enzalutamide. Some background ADT is a type of hormonal therapy...
Read MoreHow does COVID-19 affect patients with cancer undergoing chemotherapy?
In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...
Read MoreCan vitamin D levels influence the chances of survival in patients with prostate cancer?
In a nutshell This study examined the levels of vitamin D in patients with prostate cancer (PC) to see if they were linked to patients’ chances of survival. The results showed that patients with higher levels of active vitamin D had a greater chance of survival. Some background Vitamin D is made from sun exposure and can be found in two...
Read MoreShould androgen-deprivation therapy be given at the same time or before radiotherapy in the treatment of localized prostate cancer?
In a nutshell The study looked at the sequence of dose-escalated radiotherapy (RT) and androgen-deprivation therapy (ADT) in the treatment of local prostate cancer (LPCa). The study found that treatment with ADT before RT had the same outcome as treatment with ADT and RT at the same time. Some background LPCa is a form of cancer that is...
Read MoreDoes anti-clotting medication improve treatment results for patients with prostate cancer?
In a nutshell This study examined if lower numbers of platelets (blood cells involved in forming clots) and anti-clotting medications were associated with treatment results in patients with prostate cancer (PC). The authors found that lower numbers of platelets and anti-clotting medication were associated with higher treatment...
Read MoreComparing cryosurgery and hormonal therapy for locally recurrent prostate cancer after radiotherapy
In a nutshell This study compared local cryosurgery (CRYO) against androgen deprivation therapy (ADT) for the treatment of locally recurring prostate cancer (LRPC). The study found local cryosurgery had a longer overall survival (OS) when compared to ADT. Some background LRPC is cancer that has re-occurred in the prostate gland...
Read MoreWhich therapy is more effective at boosting radiotherapy effectiveness for patients with localized prostate cancer?
In a nutshell This study compared whether radiotherapy (RT) was more effective when combined with hormone therapy or brachytherapy (BT) for patients with localized prostate cancer (PC). The authors found that patients who received hormone therapy and RT survived for longer. Some background External beam radiotherapy (EBRT) focuses beams of...
Read More